New COPD drug approved – The Chart - CNN.com Blogs
Links shared publicly online about this topic.
- 468total visits
New COPD drug approved – The Chart - CNN.com Blogs
View full resource at thechart.blogs.cnn.com
Tags: COPD, COPD Medication, Disease and Condition, Diet and Nutrition, Drug, Pulmonology, disease
Most Recently Shared on March 2, 2011 at 3:34 pm By:
New #COPD drug approved - CNN.com Blogs http://t.co/GUUpLyz
New diet drug Qnexa awaits FDA approval amid safety questions – USATODAY.com
usatoday.com — “Some experts say it could potentially help dieters lose about 10% of their weight, but with its former FDA rejection, how safe is it?” View full resource at usatoday.com
Most Recently Shared on April 4, 2012 at 10:45 pm By:
Diet drug Qnexa awaits FDA approval amid safety questions http://t.co/YjlUT7Bn
Consumer Reports Warns of Lax Testing for Medical Devices - ABC News
abcnews.go.com — “Consumer Reports advises patients to do their homework before having medical devices implanted in their bodies. Companies that sell defibrillators, stents or other such products can get approval from the Food and Drug Administration without their undergoing rigorous testing, Consumer Reports warned in a new report. The FDA collects information on medical device malfunctions that lead to death. Data highlighted by Consumer Reports show 686 deaths from 2009 to last year connected to automate” View full resource at abcnews.go.com
Most Recently Shared on March 29, 2012 at 7:39 pm By:
HealthIT Policy Health News and Health IT
Consumer Reports Warns of Lax Testing for Medical Devices: Consumer Reports advises patients to do their homewor... http://t.co/z5sM68RZ
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 7:47 pm By:
Amgen Loses Monopoly on Drug for Dialysis Patients - http://t.co/O6kMuGDy #pharma
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 6:19 pm By:
Daniel Kraft Pediatrician, Internist, Health Executive, Physician, and Doctor
NYTimes: F.D.A. Approves New Anemia Drug http://t.co/WJKYbgWZ
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 10:51 am By:
Kent Bottles, MD Physician, Doctor, and Pathologist
Amgen Loses Monopoly on Drug for Dialysis Patients: http://t.co/AEiXXAfM
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 1:16 am By:
FDA Approves New Anemia Drug http://t.co/Auh0ppSW
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 7:30 pm By:
HealthTrendster Health Executive
F.D.A. Approves New Anemia Drug - A new anemia drug provides a less expensive alternative for dialysis patients and ... http://t.co/9YfRzcyE
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The F.D.A. approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 7:15 pm By:
F.D.A. Approves New Anemia Drug: A new anemia drug provides a less expensive alternative for dialysis patients a... http://t.co/4Ku4AF4F
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 6:27 pm By:
Anas Younes, M.D. Internist, Oncologist, Physician, and Doctor
F.D.A. Approves Affymax's new drug Omontys for anemic patients receiving kidney dialysis... http://t.co/2o68syVQ
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 6:21 pm By:
NYT: F.D.A. Approves New Anemia Drug http://t.co/z3CAgl33
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Xconomy
xconomy.com — “Affymax completed its surprising comeback today, as it won FDA clearance for its first marketed drug, a product for anemia that will be the first to rival a” View full resource at xconomy.com
Most Recently Shared on March 27, 2012 at 4:58 pm By:
Luke Timmerman Health Communicator
Update to Affymax FDA approval story, with comments from CEO John Orwin. Conf call coming later today. http://t.co/bG1ow9T0
Drug Dosage Was Approved Despite Warning - NYTimes.com
nytimes.com — “The Alzheimer’s drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 2:04 am By:
Brad Stuart Doctor, Internist, Pain Medicine Physician, and Physician
A new low in drug marketing + lack of regulation http://t.co/9HF6cWJR
Government ponders heart safety trials for obesity drugs - Yahoo! News
news.yahoo.com — “From Yahoo! News: WASHINGTON (Reuters) - Health regulators are asking for advice on whether, and when, heart safety studies should be required for new obesity drugs, possibly adding a new hurdle on their path to approval. An advisory panel to the Food and Drug Administration will discuss this week whether regulators should mandate such trials before the drugs can be marketed in the United States. ...” View full resource at news.yahoo.com
Most Recently Shared on March 26, 2012 at 7:06 pm By:
HealthTrendster Health Executive
Government ponders heart safety trials for obesity drugs - WASHINGTON (Reuters) - Health regulators are asking for a... http://t.co/MSNblCsb
FDA approves Teva's QNASL nasal aerosol corticosteroid
news-medical.net — “Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 7:03 pm By:
Asthma News: FDA approves Teva's QNASL nasal aerosol corticosteroid: Teva Pharmaceutical Industries Ltd. announc... http://t.co/2cZSMyF6
Government ponders heart safety trials for obesity drugs | Reuters
reuters.com — “WASHINGTON (Reuters) - Health regulators are asking for advice on whether, and when, heart safety studies should be required for new obesity drugs, possibly adding a new hurdle on their path to approval.An” View full resource at reuters.com
Most Recently Shared on March 26, 2012 at 6:02 pm By:
Government ponders heart safety trials for obesity drugs: WASHINGTON (Reuters) - Health regulators are asking fo... http://t.co/9u8Z4PR5
Advertisement
